Vincristine
- Generic Name
- Vincristine
- Brand Names
- Marqibo, Vincasar
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56N4O10
- CAS Number
- 57-22-7
- Unique Ingredient Identifier
- 5J49Q6B70F
- Background
Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...
- Indication
Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
- Associated Therapies
- -
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 87
- Registration Number
- NCT00770224
- Locations
- 🇺🇸
Doctors Hospital at Ohio Health, Columbus, Ohio, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
🇺🇸Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States
Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 55
- Registration Number
- NCT00763763
- Locations
- 🇫🇷
Service Clinique des Maladies du Sang, Paris, France
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT00718757
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Rady's Children Hospital San Diego, San Diego, California, United States
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT00671658
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00669877
- Locations
- 🇺🇸
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00651755
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 37
- Registration Number
- NCT00634179
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
- Conditions
- Interventions
- Drug: GemcitabineDrug: NavelbineDrug: Doxorubicin Hydrochloride Liposome InjectionDrug: Granulocyte-colony stimulating factor (G-CSF)Drug: PegfilgrastimDrug: CyclophosphamideDrug: VincristineDrug: LeucovorinDrug: MethotrexateDrug: Doxorubicin HydrochlorideDrug: CytarabineDrug: EtoposideDrug: CarmustineDrug: Denileukin diftitox
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 21
- Registration Number
- NCT00632827
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2015-01-14
- Target Recruit Count
- 2039
- Registration Number
- NCT00613457
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2007-12-28
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 30
- Registration Number
- NCT00581776
- Locations
- 🇺🇸
University Of Wisconsin Cancer Center, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.